All Insights
Actuarial 8 min read 18 November 2026

AT1 and Tier 2 Capital Instruments for Singapore Insurers: RBC2 Criteria Explained

Actuarial consulting: pricing and reserving analysis with loss distribution modelling

MAS has revised the eligibility criteria for AT1 and Tier 2 capital instruments issued by insurers, including a non-retail restriction. This guide explains what changed, shows a worked example of how a failed instrument affects capital resources and the PCR ratio, and sets out a practical capital planning sequence.

AT1 and Tier 2 capital instruments issued by Singapore insurers must now satisfy the eligibility criteria that MAS consulted on in March 2025 and, as reported publicly, intended to bring into effect from 1 January 2026. The criteria add conditions on top of the usual loss absorbency features, including a restriction on who may hold the instruments. For a CFO or head of capital management, the practical question is whether existing and planned hybrid instruments still count as capital resources, in what amount, and what happens to the solvency position if they do not. This article summarises the proposals and the feedback outcome as reported in public sources, and sets out how to test your capital plan against them. It is not a substitute for the MAS notices and response papers; confirm every parameter against the final instruments before relying on it.

Where AT1 and Tier 2 sit in the capital resources hierarchy

Under the risk-based capital framework for insurers, capital resources are classified by their ability to absorb losses. Tier 1 capital comprises Common Equity Tier 1 (CET1) and Additional Tier 1 (AT1). Tier 2 capital sits below it and absorbs losses mainly on a gone-concern basis. The classification matters because the framework applies quantitative limits to how much lower-quality capital can be used to meet the prescribed capital requirement (PCR) and the supervisory intervention threshold, which is the reason eligibility criteria carry real financial consequences.

The valuation and capital rules for licensed insurers are set out in the Insurance (Valuation and Capital) Regulations and the related MAS Notices, including Notice 133 for the valuation and capital framework. The second iteration of the framework, usually called RBC2, revised the calibration and the capital resources rules, and the AT1 and Tier 2 criteria are one part of that package. Treasury and actuarial teams should work from the current consolidated text rather than from earlier consultation drafts, because parameters changed between consultation and final rules.

What the March 2025 consultation proposed

The consultation focused on tightening the criteria that determine whether a debt or hybrid instrument qualifies as AT1 or Tier 2. Based on public summaries, the main themes were as follows.

  • Non-retail restriction: the instruments should be offered to and held by non-retail investors, so that loss absorption through write-down or conversion does not fall on retail holders.
  • Additional eligibility criteria: further conditions on features such as coupon discretion, call options, step-ups, loss absorption triggers and subordination.
  • Transition: arrangements for instruments already in issue, including whether they are recognised in full, phased out or grandfathered.
  • Alignment: closer consistency with the treatment of hybrid capital in the banking and group capital regimes administered by MAS.

The practical reading is that the instrument documentation, not only the instrument label, determines capital treatment. Two instruments both described as subordinated notes may sit in different tiers or fall outside capital resources entirely depending on the terms in the offering circular and trust deed.

The non-retail restriction in practice

The non-retail restriction changes the investor base for hybrid capital. Singapore insurers that previously accessed a mix of private bank and institutional demand need to confirm that the offering structure, minimum denomination, selling restrictions and secondary market transfer provisions keep the instrument out of retail hands. A legal opinion that addresses this point is advisable before issue, and the instrument should contain a covenant or transfer restriction that survives resale.

Three questions are worth asking of every instrument in issue or in the pipeline.

  1. Was it, or will it be, offered only to institutional and accredited investors under the Securities and Futures Act exemptions, and does the documentation say so?
  2. Do the terms restrict onward transfer to retail investors, and is there an operational process to enforce the restriction through custodians?
  3. Does the restriction apply to the whole life of the instrument, or only at primary issuance?

If any answer is uncertain, treat the instrument as at risk of failing the criteria until counsel and MAS confirm otherwise. Early engagement with your MAS supervisor is the normal route for any instrument where the position is not clear.

Capital planning impact: a worked example

The numbers below are hypothetical and are included only to show the mechanics. They do not describe any actual insurer.

Assume an insurer reports the following, in millions of Singapore dollars.

  • CET1 capital: 300
  • AT1 instrument: 60
  • Tier 2 instrument A: 80
  • Tier 2 instrument B: 40
  • Prescribed capital requirement: 360

Before testing the criteria, total capital resources are 480 and the ratio to the PCR is 133 percent. Suppose instrument B fails one of the additional criteria because its transfer provisions do not prevent sale to retail investors. If B is excluded in full, total capital resources fall to 440 and the ratio to the PCR falls to about 122 percent. If the AT1 instrument also fails, Tier 1 falls to 300 and the insurer must also check whether the remaining Tier 2 is within any applicable limit relative to Tier 1, which could reduce recognised Tier 2 further.

The example shows why the exercise should be run at the level of each instrument and each tier, not on total hybrid capital alone. The result also feeds the ORSA, because a loss of recognised capital changes the insurer's own view of its solvency needs and its capital management actions.

Equity counter-cyclical adjustment and its interaction with capital resources

The RBC2 changes also include an equity counter-cyclical adjustment, which in broad terms dampens the effect of equity market falls on the capital requirement for equity risk so that insurers are not forced into pro-cyclical selling. Public summaries describe it as a mechanism that adjusts the equity risk charge according to where equity prices sit relative to a longer-run reference level.

The adjustment is relevant to this topic for a specific reason. An insurer with a large equity portfolio can see its required capital move with the market while the amount of qualifying AT1 and Tier 2 stays fixed, so the headroom provided by hybrid capital is not static. Capital planning should therefore combine the instrument eligibility test with a sensitivity of the PCR to equity market movements, and the actuarial function should show the board how both move together under the stress scenarios in the ORSA. Check the final calibration of the adjustment in the current MAS Notice rather than relying on the consultation parameters.

Preparing for capital raising

Insurer capital raising in Singapore through AT1 and Tier 2 issuance needs earlier coordination between treasury, actuarial, legal and compliance than it did before the revised criteria. A sensible sequence is as follows.

  1. Inventory every capital instrument, with the key terms: tier, coupon features, call dates, loss absorption triggers, governing law, holders and transfer restrictions.
  2. Test each term against the final criteria and record the conclusion with a reference to the paragraph relied on.
  3. Quantify the capital impact of a failed or partial recognition, as in the worked example, including the effect on any internal capital target above the regulatory minimum.
  4. Agree with your MAS supervisor the treatment of any instrument that is unclear, and the transition position for instruments already in issue.
  5. Update the capital management plan, the ORSA and any dividend or capital distribution policy that relies on the current hybrid capital stock.
  6. For new issuance, build the non-retail restriction into the term sheet, the offering documents and the distribution mandate from the start, and confirm tier classification in writing with MAS before pricing where the structure is novel.

Boards and audit committees should receive the outcome of steps 2 and 3, because a change in recognised capital can affect declared solvency, rating agency discussions and the covenants in any reinsurance or financing arrangements that reference the capital ratio.

Governance and evidence

MAS supervisors will expect to see the analysis and the decision trail. Keep the instrument term analysis, the legal opinions, the actuarial calculation of the capital impact and the board paper in one file that can be produced on request. For groups, check whether the instrument is issued by the licensed insurer or by a holding company, because the capital treatment can differ between solo and group level, and the group capital rules for a designated financial holding company are changing separately.

How Alpha Consultant can help

If you are issuing, refinancing or reviewing hybrid capital, our risk-based capital team can test your instruments against the revised criteria, quantify the effect on your capital resources and PCR ratio, and prepare the supporting analysis for your board and for MAS. Contact Alpha Consultant to scope an instrument-by-instrument capital review.

Questions about how this applies to your organisation? Our consultants are available to discuss your specific position.